GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Rapid Dose Therapeutics DOSE.CN · CAD

N/A · Canadian Securities Exchange · 🇨🇦 Canada

Compare

0.10

-9.52%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CAD, from our data supplier.

FY2026

Revenue

C$2.8m

FY2017FY2026

Net income

−C$3.4m

FY2017FY2026

Free cash flow

−C$271,293

FY2017FY2026

Shareholders' equity

−C$7.2m

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
RevenueC$2.8mC$2.1mC$1.0mC$718,298C$1.8mC$262,805C$101,498———
Gross profitC$1.4mC$1.2mC$563,409C$372,404C$1.3mC$207,454C$37,337———
Research and developmentC$33,188C$148,247C$427,798C$92,885C$359,290C$85,310C$272,718C$12,991C$12,435—
Operating income−C$2.2m−C$4.2m−C$3.1m−C$3.5m−C$4.3m−C$2.1m−C$7.5m−C$653,572−C$50,079−C$50,100
Net income−C$3.4m−C$5.4m−C$4.3m−C$3.8m−C$8.5m−C$2.3m−C$8.0m−C$653,572−C$50,079−C$50,100
Diluted earnings per share-0.03-0.04-0.04-0.04-0.08-0.03-0.10-0.12-0.04-0.01

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assetsC$3.3mC$1.6mC$1.9mC$2.2mC$3.1mC$3.8mC$4.3mC$5.8mC$17,064C$17,100
Cash and short-term investments—————————C$17,100
Total liabilitiesC$10.5mC$6.8mC$5.0mC$4.9mC$2.8mC$5.4mC$4.4mC$2.0mC$29,839C$29,800
Debt——C$2.1mC$186,957——————
Shareholders' equity−C$7.2m−C$5.2m−C$3.2m−C$2.7mC$251,561−C$1.6m−C$147,783C$3.8m−C$12,775−C$12,800
Shares outstanding135m130m118m104m103m81m77m5m1m6m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−C$270,394−C$1.1m−C$2.3m−C$863,917−C$3.0m−C$1.6m−C$3.0m−C$2.1m−C$805,194−C$58,000
Capital spending−C$899−C$5,740——−C$40,356−C$9,124−C$1.2m−C$1.7m−C$208,387—
Free cash flow−C$271,293−C$1.2m−C$2.3m−C$863,917−C$3.0m−C$1.6m−C$4.3m−C$3.8m−C$1.0m−C$58,000

Latest quarters

By quarter end

May 2026Feb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024
RevenueC$584,520C$660,515C$657,135C$672,921C$782,741C$668,577C$501,689C$515,916
Gross profitC$311,859C$285,150C$309,796C$376,450C$391,711C$325,025C$270,334C$327,996
Operating income−C$227,726−C$436,029−C$688,351−C$542,787−C$504,047−C$1.3m−C$1.0m−C$857,513
Net income−C$503,696−C$700,002−C$1.1m−C$825,474−C$723,677−C$1.7m−C$1.4m−C$1.1m
Diluted earnings per share-0.00-0.01-0.01-0.01-0.01-0.01-0.01-0.01
Capital spending——−C$2.0m—————
Total assetsC$3.1mC$3.3mC$3.8mC$4.2mC$4.0mC$1.6mC$1.7mC$1.7m
Debt——————C$2.6mC$2.4m
Shareholders' equity−C$7.5m−C$7.2m−C$6.6m−C$5.9m−C$5.3m−C$5.2m−C$4.1m−C$3.8m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue56.9%60.2%—
Operating income-15.1%0.4%46.7%
Net income-3.8%8.1%53.4%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin52.3%52.7%58.4%—
Operating margin-130.6%-196.6%-225.3%—
Net margin-181.0%-256.3%-321.6%—

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings-4.2-3.1-6.0-4.5-1.1-18.3-3.0-3.1-22.1-8.3
Price to sales5.18.125.423.85.3159.6239.2———

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.